Bicycle Therapeutics (BCYC) Q2 2026 earnings summary

Executive summary

• Focused on developing Bicycle® molecules for oncology, leveraging a proprietary phage display platform and presenting new clinical data supporting improved benefit/risk profiles.

• Strategic reprioritization in March 2026 shifted focus to next-generation therapeutics, including nuzefatide pevedotin and BRC molecules, with a 30% workforce reduction to cut annual operating expenses by ~50%.

• Collaboration agreements with Bayer, Novartis, and Genentech were terminated or are being wound down, impacting near-term revenue.

• Expanded Clinical Advisory Board with the addition of Professor Thomas Powles, a leader in urothelial cancers.

• Pipeline focus on nuzefatide pevedotin and next-generation Bicycle conjugates, including radioconjugates.

Financial highlights

• Cash and cash equivalents were $510.1M as of June 30, 2026, down from $628.1M at December 31, 2025, expected to fund operations for at least 12 months.

• Collaboration revenue was $0.6M for Q2 2026, down from $2.9M in Q2 2025; $1.5M for H1 2026, down from $12.9M in H1 2025.

• Net loss for Q2 2026 was $50.3M ($0.72 per share), compared to $79.0M ($1.14 per share) in Q2 2025; H1 2026 net loss was $111.2M (vs. $139.7M in H1 2025).

• Operating expenses for Q2 2026 were $55.2M, down from $89.5M in Q2 2025, mainly due to reduced R&D and G&A costs.

• Research and development expenses for Q2 2026 were $41.2M, down from $71.0M in Q2 2025; general and administrative expenses for Q2 2026 were $14.0M, down from $18.5M in Q2 2025.

Outlook and guidance

• Remaining deferred revenue of ~$33.2M from Bayer to be recognized in Q3 2026 following collaboration termination.

• Cash runway expected to extend into 2030, supporting ongoing and planned clinical programs.

• Phase 2 trial for nuzefatide in recurrent pancreatic cancer is actively enrolling, with first patient dosed in April 2026.

• Phase 1 trial for BT1702, an MT1-MMP targeting radioconjugate, expected to begin in 2027.

• Expenses and capital requirements expected to decrease in the near term due to cost-saving initiatives, but substantial additional funding will be needed for long-term growth.